Literature DB >> 22917757

Computerised assistance for warfarin dosage--effects on treatment quality.

Ivar Dimberg1, Bartosz Grzymala-Lubanski, Anette Hägerfelth, Mårten Rosenqvist, Peter Svensson, Anders Själander.   

Abstract

BACKGROUND: Well-managed warfarin treatment with a high time in therapeutic range (TTR) corresponds to fewer bleedings or thromboembolic complications. Many small centres manage their warfarin dosing manually, with little or no knowledge of their treatment quality as measured by TTR. AuriculA is a Swedish National web-based anticoagulation dosing system. Our hypothesis was that the web based dosing system, compared to manual dosing, would improve the TTR.
METHODS: Retrospective cohort study of medical records from patients with atrial fibrillation on warfarin treatment from two centres, with previously manual warfarin dosing regimens. Data for calculation of TTR was extracted manually from medical records from the time when using manual dosing and compared with the computerised regimen.
RESULTS: In centre 1, the mean TTR was significantly increased after the introduction of AuriculA, from 64.3% (95% CI 58.8-69.8) to 71.3% (95% CI 67.7-74.8), p=0.03. In centre 2, a high TTR of 73.6% (95% CI 71.3-75.9) was maintained after the implementation, 74.0% (95% CI 71.6-76.3). INR tests were prescribed significantly more frequent after the introduction of AuriculA in both centres; 20% more often at centre 1 and 21% at centre 2.
CONCLUSION: Computerised dosing assistance within the Swedish national quality registry AuriculA improves or maintains a high treatment quality with warfarin as measured by TTR.
Copyright © 2012 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22917757     DOI: 10.1016/j.ejim.2012.07.011

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  6 in total

1.  Cost effectiveness of rivaroxaban for stroke prevention in German patients with atrial fibrillation.

Authors:  Alexander Mensch; Stephanie Stock; Björn Stollenwerk; Dirk Müller
Journal:  Pharmacoeconomics       Date:  2015-03       Impact factor: 4.981

2.  Patient compliance with an anticoagulation management system based on a smartphone application.

Authors:  Yetao Li; Li Dong; Daokang Xiang; Yongchun Zhang; Xinbu Chen; Juan Long; Xiulun Liu; Hailin Li; Yile Yi; Yongfeng Fan; Qihua Gong; Min Luo
Journal:  J Thromb Thrombolysis       Date:  2019-08       Impact factor: 2.300

Review 3.  Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review.

Authors:  Elizabeth S Mearns; Jessica Hawthorne; Ju-Sung Song; Craig I Coleman
Journal:  BMJ Open       Date:  2014-06-20       Impact factor: 2.692

4.  Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression.

Authors:  Elizabeth S Mearns; C Michael White; Christine G Kohn; Jessica Hawthorne; Ju-Sung Song; Joy Meng; Jeff R Schein; Monika K Raut; Craig I Coleman
Journal:  Thromb J       Date:  2014-06-24

5.  Triple therapy after PCI - Warfarin treatment quality and bleeding risk.

Authors:  Daniel Wadell; Jens Jensen; Erling Englund; Anders Själander
Journal:  PLoS One       Date:  2018-12-18       Impact factor: 3.240

6.  Warfarin treatment among Finnish patients with atrial fibrillation: retrospective registry study based on primary healthcare data.

Authors:  Taru Hallinen; Erkki J Soini; Christian Asseburg; Pekka Kuosmanen; Ari Laakkonen
Journal:  BMJ Open       Date:  2014-02-27       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.